Value Added Technology Co Ltd

Value Added Technology Co Ltd maintains a strong liquidity position, with a current ratio of 3.1, indicating the company can cover its short-term liabilities more than three times over. The company's liquidity_fpt score is high, supported by a free cash flow of 43,166,347,670 KRW and a total cash position that exceeds its long-term debt of 44,264,604,800 KRW. However, the risk assessment notes a key flag: net cash is negative after subtracting total debt, suggesting potential liquidity constraints if cash flow were to decline. Profitability metrics show the company is performing well relative to industry norms. The return on equity (ROE) of 8.1% and return on assets (ROA) of 5.82% are both above the industry median for Advanced Medical Equipment & Technology firms. The company's operating margin of 12.8% (calculated from operating income of 54,524,696,040 KRW on revenue of 426,416,122,880 KRW) is also robust, indicating efficient cost management and pricing power. Geographically, the company's revenue is concentrated in South Korea, with no disclosed international segments. This concentration may expose the company to local economic and regulatory risks, though the domestic healthcare market remains stable and growing. The company does not report segment-specific revenue, but its product portfolio includes diagnostic imaging systems and related software, which are core to its business model. The company's growth trajectory is positive, with a current FY outlook indicating a revenue increase of 12.3% year-over-year. The next FY is projected to see a 9.8% growth, driven by expansion in domestic healthcare infrastructure and increased demand for diagnostic equipment. Historical revenue growth has averaged 10.5% annually over the past five years, suggesting a consistent upward trend. Risk factors include the company's reliance on a narrow product portfolio and domestic market exposure. The risk assessment assigns a medium liquidity risk and a low dilution risk, with no near-term pressure from equity issuance. The company's debt-to-equity ratio of 0.09 is low, and its capital structure is conservative, with long-term debt representing only 6.4% of total assets. However, the negative net cash position after debt is a concern for liquidity risk. Recent events include a Q4 earnings report that exceeded analyst expectations, with net income of 40,127,291,650 KRW. The company also announced a new product launch in early 2026, targeting the growing demand for AI-assisted diagnostic tools. Analysts have issued a mean price target of 29,250 KRW, with a strong buy recommendation from one analyst and buy ratings from two others.